This Weight-Loss Drug Stock Could Gain 200%. The Case for It to Challenge Novo, Lilly.
In This Article:
There are several potential challengers to Novo Nordisk and Eli Lilly’s obesity drugs, and Jefferies analysts see one as particularly promising.